Project Grant R16NS150246
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $608K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Johnson City, TN 37614, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic Jacksonville $599,699 on July 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop chimeric antigen receptor T-cell and tumor-infiltrating lymphocyte immunotherapies targeting glioblastoma. The research applies a "double-hit" strategy combining two adoptive T-cell therapies administered via Ommaya reservoir to bypass the...
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Institute of Neurological Disorders and Stroke awarded Emory University $174,296 on December 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to study the dynamics of chromosomal instability in glioblastoma within the neural microenvironment. The recipient will investigate chromosomal instability (CIN) and extrachromosomal DNA (ecDNA) formation in glioblastoma tumors using human-induced pluripotent stem...
- The National Institute of Neurological Disorders and Stroke awarded Albert Einstein College of Medicine $219,372 on May 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) for a five-year career development and research initiative investigating myeloid cell reprogramming in the glioblastoma microenvironment through extracellular vesicles as a therapeutic target. The funded research seeks to advance immune function rescue in...
- The National Institute of Neurological Disorders and Stroke awarded Georgetown University $429,000 on April 16, 2026, to investigate epigenetic biomarkers in glioblastoma under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research identifies and characterizes novel epigenetic pathways controlling tumor antigens in glioblastoma, with focus on the polycomb group ring finger 1 (PCGF1) as a regulator of the GD2 CAR T cell antigen....
- The National Cancer Institute awarded The Ohio State University $567,754 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on immunotherapy for glioblastoma by targeting an immunoregulatory neuropeptide. The research addresses glioblastoma (GBM), the most lethal primary brain tumor, which exhibits remarkable resistance to immunotherapy due to CD8 T cell exclusion and dysfunction driven by immunosuppressive myeloid cells, particularly tumor-associated...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026. The recipient will conduct research into epigenetic regulation of glioblastoma stem-like cells, specifically exploring how the arginine methyltransferase CARM1 controls NGFR and NTRK signaling pathways. The work encompasses two primary aims: testing...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $127,983 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support mechanistically guided immunometabolic CAR-TIL therapy research for glioblastoma. The award funds development and evaluation of dual-engineered ME1-armored anti-PD-L1 CAR tumor-infiltrating lymphocytes in combination with intracranial administration of clemastine and bexarotene to address tumor heterogeneity and immune suppression in...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded The Trustees of The University of Pennsylvania $668,864 on June 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development of a biomarker to predict patient response to chimeric antigen receptor (CAR) T cell therapy for glioblastoma and to identify mechanisms of tumor resistance to CAR T treatment. The research employs...